PKB (protein kinase B), also known as Akt, is a key component of insulin signalling. Defects in PKB activation lead to insulin resistance and metabolic disorders, whereas PKB overactivation has been linked to tumour growth. Small-molecule PKB inhibitors have thus been developed for cancer treatment, but also represent useful tools to probe the roles of PKB in insulin action. In the present study, we examined the acute effects of two allosteric PKB inhibitors, MK-2206 and Akti 1/2 (Akti) on PKB signalling in incubated rat soleus muscles. We also assessed the effects of the compounds on insulin-stimulated glucose uptake, glycogen and protein synthesis. MK-2206 dosedependently inhibited insulin-stimulated PKB phosphorylation, PKBβ activity and phosphorylation of PKB downstream targets (including glycogen synthase kinase-3α/β, proline-rich Akt substrate of 40 kDa and Akt substrate of 160 kDa). Insulinstimulated glucose uptake, glycogen synthesis and glycogen synthase activity were also decreased by MK-2206 in a dosedependent manner. Incubation with high doses of MK-2206 (10 μM) inhibited insulin-induced p70 ribosomal protein S6 kinase and 4E-BP1 (eukaryotic initiation factor 4E-binding protein-1) phosphorylation associated with increased eEF2 (eukaryotic elongation factor 2) phosphorylation. In contrast, Akti only modestly inhibited insulin-induced PKB and mTOR (mammalian target of rapamycin) signalling, with little or no effect on glucose uptake and protein synthesis. MK-2206, rather than Akti, would thus be the tool of choice for studying the role of PKB in insulin action in skeletal muscle. The results point to a key role for PKB in mediating insulin-stimulated glucose uptake, glycogen synthesis and protein synthesis in skeletal muscle.
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INTRODUCTION
PKB (protein kinase B), also known as Akt, a serine/threonine kinase, is a key mediator of insulin and growth factor signalling downstream of PI3K (phosphoinositide 3-kinase). PKB regulates a wide range of physiological responses, including metabolism, cell proliferation and survival [1] . Hyperactivation of PI3K/PKB signalling occurs in the majority of solid tumours, and strategies that reduce PKB activity or expression can suppress tumorigenesis and improve therapeutic efficacy [2] [3] [4] . For these reasons, a variety of small-molecule PKB inhibitors have been developed as potential anticancer drugs [5] . However, PKB inhibition could induce insulin resistance because metabolic control by insulin involves PKB. For example, PKB mediates insulin-stimulated glucose uptake [6, 7] and protein synthesis [8, 9] in skeletal muscle, thereby controlling glucose homoeostasis and muscle growth respectively.
PKB activation requires phosphorylation at Thr 308 and Ser 473 by PDK1 (phosphoinositide-dependent kinase 1) and the rapamycininsensitive mTORC [mTOR (mammalian target of rapamycin) complex] 2 respectively [10, 11] . This occurs following PKB binding to 3-phosphoinositides on intracellular membranes via its PH (pleckstrin homology) domain, thereby inducing a conformational change allowing phosphorylation by upstream kinases [10] . Once activated, PKB phosphorylates a panoply of downstream targets [1] . GSK3 (glycogen synthase kinase 3) was the first PKB substrate to be identified [10] . GSK3α/β is constitutively active and its phosphorylation by PKB leads to inactivation. GS (glycogen synthase) would thus be in its active dephosphorylated state for glycogen synthesis [12] . Since the discovery of GSK3, an increasing number of PKB substrates have been identified, many of which relay the effects of insulin to cell function. For example, PKB phosphorylates AS160 (Akt substrate of 160 kDa), also known as TBC1D4 (TBC1 domain protein 4), which decreases its Rab-GAP (GTPase-activating protein) activity, allowing the conversion of Rab proteins into their active GTP-bound states required for insulin-stimulated GLUT (glucose transporter) 4 translocation to the plasma membrane [13] . Insulin, via PKB, also enhances protein synthesis via indirect activation of mTORC1 by phosphorylating TSC2 (tuberous sclerosis complex 2) and PRAS40 (proline-rich Akt substrate of 40 kDa) [14, 15] . TSC2 and PRAS40 are negative regulators of mTORC1 and their phosphorylation by PKB opposes their inhibitory action on mTORC1. Subsequent mTORC1 activation leads to downstream p70S6K (p70 ribosomal protein S6 kinase) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) phosphorylation, thereby increasing cell growth and capdependent translation initiation respectively.
Our understanding of PKB function in insulin action stems from studies on genetic mouse models in which PKB isoforms were deleted [7, 16] or from loss-or gain-of-function strategies involving siRNA (small interfering RNA)-mediated knockdown or overexpression of constitutively active/dominantnegative PKB constructs [8, 17, 18] . These approaches provided important clues for clarifying the role of PKB, but suffer from drawbacks, including overexpression-induced artefacts and longterm developmental changes. As an alternative, pharmacological inhibitors offer the possibility of inhibiting endogenous PKB acutely without unwanted compensatory effects. Previously, wortmannin was used to test the role of PKB activation in insulin action by blocking PI3K activation [19] [20] [21] , but obviously cannot be used to investigate signalling downstream.
Owing to many off-target effects encountered with ATPcompetitive PKB inhibitors, allosteric PKB inhibitors have been developed [22] . Akti-1/2 (referred to as Akti hereinafter) prevents phosphorylation-induced PKB activation by interacting with the PH domain, which makes PKB a poor substrate for the upstream kinases [23] . These inhibitors have been shown to inhibit PKB in vitro in the nanomolar range and display high specificity over a panel of other kinases, including PI3K, PDK1 and mitogenactivated protein kinases [24, 25] . Akti has been used to validate therapeutic PKB targeting in cancer research [26] and also to study the role of PKB in the control of glucose [23] and fat metabolism [27] . However, the specificity of Akti was recently questioned in 3T3-L1 adipocytes where it decreased insulinstimulated glucose uptake independently of its effect on PKB activity [28] . MK-2206 is a new compound related to Akti and is undergoing clinical trials for the treatment of advanced solid tumours [25] . MK-2206 inhibits recombinant PKB at least 10-fold more potently than Akti [22, 25] and, in 3T3-L1 adipocytes, MK-2206 displayed improved specificity in inhibiting PKB and insulin-stimulated GLUT4 translocation/glucose transport [29] . In the present study, we evaluated the effects of MK-2206 and Akti on PKB phosphorylation/activation in incubated rat skeletal muscles and assessed their impact on insulin-stimulated glucose metabolism and protein synthesis in relation to the inhibition of signalling downstream of PKB.
MATERIALS AND METHODS

Materials
MK-2206 was kindly provided by Dario Alessi (Dundee University, Dundee, U.K.). Akti (also called Akti inhibitor VIII) and wortmannin were purchased from Calbiochem. Insulin (Actrapid) was from Novo Nordisk. 2-Deoxy-D- [1- 3 H]glucose and HRP (horseradish peroxidase)-conjugated anti-rabbit antibody were purchased from GE Healthcare. 
Skeletal muscle incubations
Rats were anaesthetized (intraperitoneally with sodium pentobarbital, 50 mg/kg). Soleus muscles were rapidly dissected, split longitudinally into two strips of similar size and suspended in the incubation apparatus at the resting length. The muscles were equilibrated for approximately 20 min in KHB (KrebsHenseleit bicarbonate) buffer (120 mM NaCl, 4.7 mM KCl, 1.25 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 2.5 mM CaCl 2 and 25 mM NaHCO 3 , pH 7.4) containing 5.5 mM glucose, 2 mM sodium pyruvate and 0.1 % BSA. After equilibration, the muscles were pre-incubated for 30 min with either 0.1 % DMSO as vehicle control or the indicated inhibitor concentrations followed by incubation with and without insulin (10 m-units/ml) for 30 min. The incubations were gassed continually with 95 % O 2 /5 % CO 2 . To induce contraction, the muscles were electrically stimulated for 30 min with 200 ms trains delivered every 2 s at 100 Hz and 10 V as described in [30] . The muscles were then blotted rapidly on filter paper and frozen in liquid nitrogen.
Culture of L6 myotubes
L6 rat skeletal muscle cells (passaged four to ten times) were maintained in DMEM (Dulbecco's modified Eagle's medium) containing 4.5 g/l glucose supplemented with 10 % (v/v) fetal bovine serum, 50 units/ml penicillin and 50 μg/ml streptomycin at 37
• C under a 5 % CO 2 atmosphere. The cells were seeded in 24-well plates at a density of 3.5×10 4 cells/well. When the cells had reached 90 % confluence, differentiation was induced by switching to DMEM containing 1 g/l glucose supplemented with 2 % (v/v) fetal bovine serum. The cells were allowed to differentiate for 3 days before experiments were performed as described in the Figure legends.
Metabolic parameters and GS activity
Glucose uptake, glycogen synthesis, protein synthesis and GS activities were measured as described in the Supplementary Online Data at http://www.BiochemJ.org/bj/447/bj4470137add.htm.
Preparation of muscle lysates
Muscles were weighed and homogenized in ice-cold lysis buffer (15 μl/mg of wet weight) containing 50 mM Hepes, 50 mM KCl, 50 mM NaF, 5 mM Na 4 P 2 O 7 , 5 mM 2-glycerophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 1 mM dithiothreitol and a protease inhibitor cocktail (Roche) twice for 15 s using an UltraTurrax instrument. The homogenates were rotated with 1 % (v/v) Triton X-100 at 4
• C for 1 h and centrifuged at 20 000 g for 15 min at 4
• C for the estimation of lysate protein concentration.
Total PKB and PKBβ assay
Total PKB and PKBβ activities were measured as described in [31] , with modifications. Briefly, muscle lysates (containing 500 μg of protein) were immunoprecipitated either with 2 μg of anti-(PKB PH domain) antibody (for total activity) or with 2 μg of anti-PKBβ antibody (for PKBβ activity) pre-bound to 20 μl of Protein G-Sepharose. The immunoprecipitates were washed twice with 0.5 ml of lysis buffer and once with 0.5 ml of buffer A (containing 10 mM Mops, pH 7.0, 0.5 mM EDTA, 0.1 % 2-mercaptoethanol and 10 mM magnesium acetate). Protein kinase activity was then measured in a final volume of 50 μl of buffer A supplemented with 2 mM dithiothreitol, 0.02 % Brij 35, 200 μM substrate peptide and 0.1 mM [γ -32 P]ATP (specific radioactivity of 1000 c.p.m./pmol). After 30 min of incubation at 30
• C with continual gentle mixing, 20 μl aliquots of supernatant were taken and spotted on to Whatman P81 papers for the determination of 32 P-incorporation by scintillation counting. • C). After blocking, the membranes were washed briefly in TBS-T and then incubated overnight at 4
• C with primary antibodies. After washing three times with TBS-T for 10 min, the membranes were incubated with appropriate secondary antibodies for 1 h at room temperature and then washed again three times for 10 min with TBS-T. Immunoreactive bands were visualized by ECL and quantified by densitometry with ImageJ (NIH). Total eEF2 was used as a loading control.
Other methods
Protein concentrations were determined as described in [32] using BSA as a standard. Results are means + − S.E.M. Statistical analysis was performed using a Student's unpaired t test and P < 0.05 was considered significant.
RESULTS
Effects of wortmannin on insulin-stimulated glucose uptake and PKB signalling in incubated soleus muscles
We first used wortmannin as a reference compound for establishing dose-response effects on insulin-stimulated glucose uptake and PKB signalling in incubated soleus muscles (Table 1 and Supplementary Figure S1 at http://www.BiochemJ.org/bj/ 447/bj4470137add.htm). Insulin stimulated glucose uptake more than 3-fold in this ex vivo skeletal muscle model (Supplementary Figure S1A) . Phosphorylation of PKB at both Thr 308 and Ser 473 was dramatically increased in response to insulin treatment (Supplementary Figure S1B) . Insulin-stimulated glucose uptake was decreased dose-dependently by wortmannin, becoming significant at 0.1 μM, and being almost completely abolished at a concentration of 0.5 μM (Supplementary Figure S1A) ; IC 50 250 nM (Table 1) , as reported previously [33, 34] . A significant decrease in insulin-induced PKB phosphorylation was already observed in muscles pre-treated with 0.05 μM wortmannin, being almost completely suppressed at a concentration of 0.5 μM Figure S1B) . Thus the insulin-induced increase in PKB phosphorylation was approximately 5-fold more sensitive to inhibition by wortmannin than insulin-stimulated glucose uptake ( Table 1 ). The inhibition of the insulin-induced increases in downstream GSK3α Ser 21 and PRAS40 Thr 246 phosphorylation were also more sensitive to wortmannin than was its effect on glucose uptake (Table 1 and Supplementary Figure S1C) . The potency of inhibition of the insulin-induced rises in GSK3β Ser 9 and AS160 Thr 642 phosphorylation were comparable with the sensitivity of inhibition of insulin-stimulated glucose uptake by wortmannin ( Table 1) .
Effects of MK-2206 and Akti on insulin-stimulated PKB and downstream target phosphorylation in incubated soleus muscles
In incubated soleus muscles, insulin substantially increased the phosphorylation of PKB at Ser 473 and Thr 308 , together with a range of its downstream targets, including GSK3α/β (Ser 21 /Ser 9 ), AS160 (Thr 642 ) and PRAS40 (Thr 246 ) (Figure 1 ). Pre-incubation with MK-2206 reduced insulin-induced PKB phosphorylation at both Ser 473 and Thr 308 in a dose-dependent manner such that, at a concentration of 20 μM, almost complete (98 %) inhibition of insulin-stimulated PKB phosphorylation was observed ( Figure 1B) . The IC 50 values for the inhibition of insulininduced PKB Ser 473 and Thr 308 phosphorylation by MK-2206 were 0.9 μM and 0.6 μM, 3-5-fold more sensitive than the inhibition of insulin-stimulated glucose uptake respectively (Table 1) . MK-2206 reduced insulin-stimulated PKB downstream target phosphorylation ( Figures 1C and 1D ) with a potency comparable with the inhibition of insulin-stimulated glucose uptake (Table 1) . However, for insulin-stimulated AS160 Thr 642 phosphorylation, much higher doses, above 10 μM MK-2206, were required for half-maximal inhibition ( Figure 1D and Table 1 ). Also, preincubation with 20 μM MK-2206 did not completely block insulin-stimulated AS160 phosphorylation ( Figures 1A and 1D) .
Pre-incubation of soleus muscles with Akti had only modest inhibitory effects on insulin-induced PKB and downstream target phosphorylation (Figure 1) . A slight approximate 30 % decrease in insulin-stimulated PKB Ser 473 and Thr 308 phosphorylation became apparent at 1 μM Akti ( Figure 1F ), but increasing Akti concentrations up to 20 μM did not inhibit insulin-induced PKB phosphorylation much further (∼ 40 % inhibition at Ser 473 and ∼ 60 % inhibition at Thr 308 ). Consistent with the modest inhibition of PKB phosphorylation by insulin, Akti slightly inhibited insulinstimulated GSK3α/β and PRAS40 phosphorylation ( Figures 1G  and 1H ). However, insulin-stimulated AS160 phosphorylation was not significantly affected by Akti concentrations up to 20 μM ( Figure 1H ).
We also tested the effects of MK-2206 and Akti upstream of PKB in insulin signalling by immunoblotting the muscle extracts for IRS1 Tyr 612 phosphorylation. This site lies downstream of the insulin receptor kinase and, upon phosphorylation, binds to an SH2 (Src homology 2) domain in the p85 subunit of PI3K, resulting in activation of the p110 catalytic subunit [35] . Representative blots for this site are shown in Figures 1(A) and 1(E) and quantification of the data is presented in Supplementary Figure S2 at http://www.BiochemJ.org/bj/447/ bj4470137add.htm. Pre-incubation with MK-2206 or Akti had no effect on insulin-induced IRS1 Tyr 612 phosphorylation (Supplementary Figure S2) .
Effects of MK-2206 and Akti on insulin-stimulated glucose uptake and PKBβ activity in incubated soleus muscles
Insulin increased glucose uptake in incubated soleus muscles at least 3-fold (Figures 2A and 2B) . Pre-incubation of the muscles with 5 μM MK-2206 reduced insulin-stimulated glucose uptake by ∼ 60 % and further reduced insulin-stimulated glucose uptake by ∼ 80 % at a concentration of 20 μM (Figure 2A ). Preincubation of the muscles with 1 μM Akti significantly decreased insulin-stimulated glucose uptake (by ∼ 30 %), but increasing the concentration of the compound up to 20 μM did not significantly improve its inhibitory effect ( Figure 2B ).
PKBα and PKBβ are the major isoforms activated by insulin in skeletal muscle [36] . Since PKBβ appears to mediate insulinstimulated glucose uptake [7] , we measured PKBβ activity for comparison with total PKB Thr 308 /Ser 473 phosphorylation ( Figures 1B and 1F ). MK-2206 was a slightly less potent inhibitor of PKBβ activity compared with phosphorylation (Table 1 and compare Figure 1B with Figure 2C ). It is noteworthy that preincubation of muscles with 20 μM MK-2206 did not completely inhibit insulin-induced PKBβ activation ( Figure 2C) , consistent with the fact that, at this concentration, insulin-stimulated glucose uptake was not fully inhibited either (Figure 2A ), whereas the insulin-induced rise in PKB Thr 308 /Ser 473 phosphorylation was almost totally abrogated ( Figure 1B ). Akti at 20 μM, on the other hand, only moderately decreased insulin-induced PKBβ activation ( Figure 2D ) and insulin-stimulated glucose uptake ( Figure 2B ). When we measured total PKB activity by immunoprecipitation with an anti-(PH domain) antibody to trap all isoforms, total PKB activity (Supplementary Figure S3 at http://www.BiochemJ.org/bj/447/bj4470137add.htm) and the phosphorylation state of PKB were closely related ( Figures 1B  and 1F ).
Effects of MK-2206 on insulin-stimulated glycogen synthesis and GS activity in incubated soleus muscles
As shown above, MK-2206 more potently inhibited insulinstimulated PKB activation and glucose uptake than Akti (Figures 1  and 2 ). Therefore, we investigated the effect of MK-2206 on insulin-stimulated glycogen synthesis. Insulin stimulated glycogen synthesis in incubated soleus muscles more than 7-fold ( Figure 3A) . Pre-incubation of the muscles with MK-2206 decreased insulin-stimulated glycogen synthesis in a dosedependent manner, becoming significant at 1 μM, and resulting in more than 90 % inhibition at concentrations of 10 and 20 μM ( Figure 3A ) (IC 50 1.8 μM; Table 1 ). MK-2206 also inhibited insulin-stimulated GS activity dose-dependently ( Figure 3B ) and more potently (IC 50 0.38 μM; Table 1 ) than insulinstimulated glycogen synthesis. Indeed, a significant decrease in insulin-stimulated GS activity was already observed in muscles pre-incubated with 0.1 μM MK-2206 ( Figure 3B ). Pre-incubation with MK-2206 (5-20 μM) had no effect either on basal glycogen synthesis or on basal GS activity (Figure 3) .
Effects of MK-2206 and Akti on insulin-stimulated glucose uptake in L6 myotubes
The poor inhibitory effect of Akti on insulin-induced PKB phosphorylation ( Figure 1F ), glucose uptake ( Figure 2B ) and PKBβ activation ( Figure 2D ) seen in soleus muscles was rather unexpected, given that Akti has been reported to strongly inhibit insulin-stimulated PKB activity and downstream effects in rat L6 myotubes, rat primary adipocytes and mouse 3T3-L1 adipocytes [23, 27, 28, 37] . To verify that Akti was effective with similar potency to that observed in previous studies [23] , we incubated L6 myotubes with the inhibitors before measuring insulinstimulated glucose uptake (Figure 4) . Pre-incubation with Akti inhibited insulin-stimulated glucose uptake in a dose-dependent manner ( Figure 4A) , with a calculated IC 50 of 0.19 + − 0.07 μM (n = 4), reflecting similar potency for its effect on 2-deoxyglucose uptake in L6 cells reported previously [23] . However, both Akti ( Figure 4A ) and MK-2206 ( Figure 4B ) also inhibited basal glucose uptake dose-dependently. An effect of Akti on basal glucose uptake was not observed in the previous study on L6 myotubes [23] . When we reduced the exposure time to the inhibitors (60 min) to match the protocol used by Green et al. [23] , the effect of MK-2206 on basal glucose uptake was less pronounced, whereas the inhibitory effect of Akti on basal glucose uptake was still present (results not shown). The discrepancy could be due to the different batches of L6 cells used. Also, there might be an off-target effect, as Akti has been shown to interfere with GLUT1 and GLUT4 facilitative transport activity in 3T3-L1 adipocytes [28] . At concentrations of 10 μM, neither Akti nor MK-2206 significantly affected basal glucose uptake in incubated soleus muscles ( Figure 5A ). MK-2206 elicited dosedependent inhibition of insulin-stimulated glucose uptake in L6 myotubes, but was somewhat less potent than Akti ( Figure 4B ) (IC 50 0.33 μM; Table 1 ). However, treatment with 0.5 and 1 μM MK-2206 decreased insulin-stimulated glucose uptake without significantly affecting basal glucose uptake ( Figure 4B ).
Effects of MK-2206 and Akti on contraction-induced glucose uptake in incubated soleus muscles
We conducted a series of experiments to examine the effects of MK-2206 and Akti on basal and contraction-stimulated glucose uptake to rule out the possibility that the inhibition of insulinstimulated glucose uptake by the compounds was due to interference with transporter function. Basal and contraction-stimulated glucose uptake were unaffected by pre-incubation with 10 μM concentrations of either MK-2206 or Akti ( Figure 5A ). Muscle contraction is known to stimulate glucose uptake independently of insulin signalling and probably via AMPK activation [38] . Indeed, contraction-induced increases in AMPK Thr 172 and ACC Ser 218 phosphorylation were unaffected in muscles pre-incubated with 10 μM MK-2206 or Akti (Figures 5B and 5C ).
Effects of MK-2206, Akti and wortmannin on insulin-stimulated protein synthesis in incubated soleus muscles
The rate of protein synthesis, measured by [ 3 H]phenylalanine incorporation into protein, increased by approximately 60 % in soleus muscles incubated with insulin compared with the controls ( Figure 6A ). Treatment of muscles with 10 μM MK-2206 resulted in a significant decrease in the insulin-stimulated rate of protein synthesis, whereas pre-incubation with 10 μM Akti had no effect ( Figure 6A ). Pre-incubation of muscles with 1 μM wortmannin completely abolished the increase in protein synthesis induced by insulin ( Figure 6A ). The basal rate of protein synthesis was unaffected by MK-2206, Akti or wortmannin ( Figure 6A ). Preincubation with MK-2206, Akti and wortmannin was effective, since the insulin-induced increases in PKB (Ser 473 /Thr 308 ) and GSK3α/β (Ser 21 /Ser 9 ) phosphorylation were either blocked or abrogated by the inhibitors (Figure 6B ).
Effects of MK-2206, Akti and wortmannin on the insulin-induced increases in phosphorylation state of mTORC1 signalling proteins in incubated soleus muscles
To gain more insight into the role of PKB in the regulation of protein synthesis by insulin, we measured the phosphorylation state of downstream targets and effectors of mTORC1 signalling ( Figure 7) . The basal phosphorylation of p70S6K (Thr 389 ), rpS6 (Ser 240 /Ser 244 ), 4E-BP1 (Thr 37 /Thr 46 ) and PRAS40 (Thr 246 ) was low, and pre-incubation with MK-2206, Akti or wortmannin had no significant effect on basal phosphorylation levels ( Figure 7) . Consistent with the effects of the inhibitors on the rates of protein synthesis, treatment of the muscles with 10 μM MK-2206 markedly reduced the insulin-induced increases in phosphorylation of p70S6K, rpS6, 4E-BP1 and PRAS40 (Figure 7) . Pre-incubation with Akti moderately reduced the increases in phosphorylation of p70S6K, rpS6 and PRAS40 (P = 0.06) by insulin, but had no significant effect on the insulin-induced rise in 4E-BP1 phosphorylation ( Figure 7E) . Treatment of the muscles with 1 μM wortmannin completely abolished the insulin-induced increases in phosphorylation of mTORC1 signalling components ( Figure 7) . We also examined the phosphorylation state of eEF2 ( Figure 7F ), which can be affected by mTORC1 signalling, because p70S6K has been reported to phosphorylate and inactivate its upstream eEF2 kinase [39] . Phosphorylation of eEF2 inhibits translation elongation, thus a decrease in eEF2 phosphorylation due to an increase in mTORC1 signalling would contribute to the stimulation of protein synthesis by insulin. However, incubation of soleus muscles with insulin did not significantly decrease eEF2 phosphorylation ( Figure 7F ). On the other hand, under insulin stimulation, treatment of the muscles with 10 μM MK-2206 and 1 μM wortmannin significantly increased eEF2 phosphorylation ( Figure 7F ), consistent with a reduction in insulin-stimulated protein synthesis rate by the inhibitors ( Figure 6A ).
DISCUSSION
In the present study, we compared the effects of MK-2206 and Akti on insulin-stimulated PKB activation/phosphorylation, insulin-induced phosphorylation of PKB downstream targets and the stimulation of metabolic rates by insulin in isolated rat soleus muscles. Soleus muscle is composed mainly of slowtwitch (type I) oxidative fibres. This muscle was chosen because it expresses higher levels of insulin signalling pathway components and displays better effects of insulin on metabolism compared with fast-twitch epitrochlearis muscle [40, 41] . The muscles were incubated with a high dose (10 m-units/ml) of insulin, which would result in spare activation of signalling above that required for maximal activation of glucose transport (and other functional outputs). Neither MK-2206 nor Akti affected insulin signalling upstream of PKB, as judged by immunoblotting for IRS1 Tyr 612 phosphorylation ( Figures 1A and 1E and Supplementary Figure  S2) . These results are in agreement with previous studies in which the effects of Akti were studied in L6 myotubes and rat and 3T3-L1 adipocytes [23, 27] . We found that MK-2206, rather than Akti, would be the preferred experimental tool for investigating the role of PKB on insulin action in skeletal muscle. The inhibition of insulininduced PKB activation by MK-2206 was associated with a decrease in phosphorylation state of several PKB targets, namely GSK3, AS160 and PRAS40. Our results thus support a central role for PKB in the control of insulin-stimulated glucose uptake, glycogen synthesis and protein synthesis in skeletal muscle. MK-2206 was more potent than Akti in inhibiting PKB activation and PKB downstream signalling, consistent with the physiological responses, such as insulin-stimulated glucose uptake and protein synthesis. These results are in agreement with a recent study in 3T3-L1 adipocytes showing that MK-2206 is a more potent and specific PKB inhibitor than Akt1i or Akt2i (presumed to be PKBα-or PKBβ-selective inhibitors respectively) in blocking PKB action and insulin-stimulated GLUT4 translocation [29] . The decrease in insulin-stimulated glucose uptake by MK-2206 correlated well with decreased PKBβ activity (Figures 2A and  2C) , supporting the idea from genetic models that PKBβ is the isoform responsible for controlling GLUT4 translocation [18] and glucose uptake in skeletal muscle [7] . However, there could be overlapping action of MK-2206 on PKB isoforms and it would be interesting to study the effect of PKBβ-specific inhibitors and/or activators on insulin action and test the effects of MK-2206 on insulin signalling in PKBβ-knockout mice.
We observed that, in order to decrease insulin-stimulated glucose uptake, considerable inhibition of insulin-induced PKB phosphorylation/activity was required (compare Figure 1B with Figure 2A ). In 3T3-L1 adipocytes and L6 myotubes, a small increase in PKB activity by insulin was enough to elicit robust GLUT4 translocation and maximal stimulation of glucose uptake [18, 42] . Hence, a large decrease in PKB activity would not necessarily result in a decrease in glucose uptake. Increased AS160 Thr 642 phosphorylation has been strongly implicated in promoting GLUT4 translocation by insulin [13] , but our results showed that to decrease AS160 Thr 642 phosphorylation required doses of inhibitors (MK-2206 and wortmannin) higher than those required to decrease glucose uptake. A discrepancy between the PKB-AS160 axis and glucose uptake has been observed previously [30, 37] , suggesting that AS160 phosphorylation is not the sole determinant of insulin-induced glucose transport. One can speculate that AS160 only controls GLUT4 vesicle movement to the plasma membrane, whereas the major site for regulating the extent of glucose uptake by insulin occurs at the plasma membrane involving vesicle tethering, fusion and internalization [43] . Thus the signalling molecules along the PKB axis (from PI3K/PDK1 to AS160) would act to amplify the insulin signal, explaining why a small extent of activation would be sufficient to elicit maximal downstream effects [37] . Our results also indicate that modest inhibition of the PKB to mTORC1 signalling pathway by Akti (including PKB, PRAS40, p70S6K and rpS6) was without effect on insulin-stimulated 4E-BP1 phosphorylation ( Figure 7E ) and protein synthesis ( Figure 6A ).
Pre-incubation of muscles with Akti led to a small decrease in insulin-stimulated PKB phosphorylation/activation and glucose uptake, and increasing Akti concentrations did not change its inhibitory capacity, emphasizing that Akti is not an effective tool for evaluating the role of PKB in skeletal muscle. The fact that insulin-induced PKBβ activation was only decreased at the very high Akti concentration ( Figure 2D ) might be indicative of a lack of specificity of the compound. Indeed, Akti has been shown to interfere with GLUT1 and GLUT4 facilitative transport activity in 3T3-L1 adipocytes [28] . In L6 myotubes, we observed dose-dependent and parallel decreases in basal and insulin-stimulated glucose uptake (Figure 4) , suggesting that Akti, and possibly elevated concentrations of MK-2206, might affect GLUT1, GLUT3 and GLUT4 transport activity. In incubated soleus muscles, however, basal and contraction-induced glucose uptake were unaffected by the PKB inhibitors ( Figure 5A) . Overall, the results do suggest a potential off-target effect of Akti in skeletal muscle that is insulin-dependent, emphasizing the caution that needs to be exercised with the use of this inhibitor.
The dose-dependent inhibition of insulin-stimulated glycogen synthesis by MK-2206 correlated well with the decrease in insulin-stimulated GS activity ( Figure 3 ). GS activity is controlled both by allosteric stimulation by glucose 6-phosphate and by reversible multi-site phosphorylation [44] . GS is activated by dephosphorylation, particularly at sites phosphorylated by GSK3 [12, 30] . Interestingly, the IC 50 values for the effects of MK-2206 on the inhibition of insulin-induced increases in PKB phosphorylation, GSK3 phosphorylation, GS activity and the rate of glycogen synthesis were not that different and around the same order of magnitude. Allosteric stimulation of GS by glucose 6-phosphate has been proposed to be the primary mechanism by which insulin increases muscle glycogen accumulation [45] with insulin-induced GSK3 phosphorylation being of little importance [46] . These conclusions were reached in 'all-or-none' scenarios using knockin mice in which wildtype genes had been replaced with mutant forms expressing GS which was insensitive to allosteric stimulation by glucose 6-phosphate or non-phosphorylatable GSK3α/β respectively. However, we have shown in the present study that graded decreases in insulin-stimulated PKB phosphorylation, PKBβ activity and GSK3α/β phosphorylation by increasing MK-2206 concentrations (Figures 1 and 2 ) led to parallel decreases in insulin-stimulated GS activity and glycogen synthesis (Figure 3 ). Since MK-2206 reduced insulin-stimulated glucose uptake (Figure 2A ), this could also reduce the allosteric stimulation of GS by decreasing intracellular glucose 6-phosphate concentrations. It is noteworthy that insulin-stimulated glycogen synthesis and certainly GS activation were more sensitive to MK-2206 than insulin-stimulated glucose uptake (Table 1) . At a 1 μM concentration of inhibitor, insulin-induced glucose uptake was unaffected (Figure 2A) , whereas insulin-stimulated glycogen synthesis and mainly GS activation were inhibited (Figure 3) , thus suggesting that a decrease in glucose uptake (and glucose 6-phosphate concentration) cannot explain the decrease in glycogen synthesis, and demonstrating that GS inactivation has a role to play. Therefore, on the basis of our results, we would argue that both allosteric and phosphorylation mechanisms of control of GS are important determinants of insulin-stimulated glycogen synthesis in muscle.
Using MK-2206, we found that PKB inhibition substantially reduced insulin-stimulated protein synthesis, associated with decreases in the phosphorylation states of mTORC1 signalling components, namely PRAS40, p70S6K, rpS6 and 4E-BP1. Thus, on the basis of pharmaceutical inhibition, our results suggest a key role for PKB in controlling mTORC1 signalling and protein synthesis, complementing results obtained using other approaches such as genetic models or long-term overexpression [8, 9] . In the presence of insulin, MK-2206, along with wortmannin, increased the phosphorylation state of eEF2, which could also explain the reduction of insulin-stimulated protein synthesis by the inhibitors. Basal protein synthesis measured with radioactive phenylalanine was unaffected by PKB inhibitors, suggesting that the basal rate of protein synthesis is independent of PKB activity.
Although PKB-interfering drugs could be promising for cancer treatment [25, 26, 47] , an obvious undesirable effect would be the inhibition of insulin-mediating metabolic functions of PKB. Decreased insulin action by inhibiting PKB has been reported in different cell types or in pre-clinical studies [23] [24] [25] [26] 28, 29, 37] . The present study indicates that there might be a potential to induce skeletal muscle insulin resistance with PKB inhibitors used to treat cancer. A recent report from the Phase I clinical trial of MK-2206 indicated that patients with advanced solid tumours receiving MK-2206 (60-90 mg) on alternate days for 28 days displayed hyperinsulinaemia with only transient hyperglycaemia [25] . Our data show that high doses of MK-2206 would be required (>5 μM in our system) to affect insulin-stimulated muscle glucose uptake. However, low doses of MK-2206 were enough to decrease insulin-stimulated GS activation (0.1 μM) and glycogen synthesis (1 μM), suggesting that skeletal muscle insulin resistance might occur even with normal glucose clearance. Reduced GS activity has been proposed to represent a major defect in insulin resistance [44, 48] and impaired GS activation over time could cause glucose 6-phosphate accumulation and lead to a feedback inhibition on glucose uptake [49] . Therefore one might predict that the compensatory effect of hyperinsulinaemia to keep normal glucose levels would not be long-lasting in patients treated with MK-2206.
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Measurement of protein synthesis
Protein synthesis was measured by adding 1 mM phenylalanine and radioactive tracer L- [2,3,4,5,6- 3 H]phenylalanine (1 μCi/ml) to the muscle incubations (3.5 ml) at 37
• C. After 30 min, the muscles were washed twice for 5 min with ice-cold KHB (KrebsHenseleit bicarbonate) buffer and frozen. Protein synthesis was calculated from the incorporation of radioactivity into extract protein as described in [5] with the following modifications. The frozen muscles were homogenized in ice-cold buffer (15 μl per milligram of wet weight) containing 50 mM Hepes, 50 mM KCl, 50 mM NaF, 5 mM Na 4 P 2 O 7 , 5 mM 2-glycerophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 1 mM dithiothreitol and a protease inhibitor cocktail (Roche) twice for 25 s using an Ultra-Turrax instrument. The homogenates were rotated with 0.1 % Triton-X 100 at 4
• C for 1 h and protein concentrations were determined. TCA (trichloroactic acid) was added to the homogenates (containing 1 mg of protein) to a final concentration of 10 % (w/v). The samples were then vortex-mixed and left on ice for 20 min to allow protein precipitation. The mixtures were centrifuged at 4000 g for 10 min, and the protein pellets were resuspended in 1 ml of 0.1 mM NaOH. Proteins were immediately reprecipitated by adding TCA to a final concentration of 10 % (w/v). After standing on ice for 20 min, proteins were collected by centrifugation and washed twice with 1 ml of 5 % (w/v) TCA, with centrifugation at 2500 g for 5 min to collect precipitated proteins. The protein pellets were solubilized in 0.3 ml of formic acid and an aliquot (0.25 ml) was taken for liquid-scintillation counting. 
